Protease Inhibitor-Associated QT Interval Prolongation;Prolongement de l'Intervalle QT Avec les Inhibiteurs de Protéase

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages 1544-1550

  Hunt, Kimberley ^a   Hughes, Christine A ^a   Hills Nieminen, Cara ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Electrocardiogram; HIV; Protease inhibitors; QTc interval

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; EMTRICITABINE; FLURAZEPAM; INSULIN; LABETALOL; LAMIVUDINE; LISINOPRIL; LOPINAVIR; METHADONE; NELFINAVIR; OXYCODONE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DATA ANALYSIS; DIABETES MELLITUS; ELECTROCARDIOGRAM; EMBASE; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDLINE; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; TORSADE DES POINTES;

ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; HIV INFECTIONS; HUMANS; LONG QT SYNDROME; ODDS RATIO; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RISK FACTORS; TORSADES DE POINTES;

EID: 83155182932     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q422     Document Type: Article

References (35)

1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9.
2. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10,2011:1-166. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent-GL.pdf (accessed 2011 Aug 24).
3. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: guidance to industry, 2005. www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf (accessed 2011 Jun 15).
4. Van Noord C, Eijgelsheim M, Stricker BH. Drug-and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70:16-23.
5. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
6. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 2010;30:684-701.
7. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pac Clin Electrophysiol 1997;20:2810-6.
8. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005;97:1657-61.
9. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995;5:48-52.
10. Qaqa AY, Shaaban H, DeBari VA, et al. Viral load and CD4+ count as risk factors for prolonged QT interval in HIV-infected subjects: a cohortnested case-control study in an outpatient population. Cardiology 2010;117:105-11.
11. Anson BD, Weaver GR, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-6.
12. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
13. Falconer M, Molloy D, Ingerhaug J, Barry M. Methadone-induced torsade de pointes in a patient receiving antiretroviral therapy. Ir Med J 2007;100:631-2.
14. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007;44:e67-8.
15. Gallagher DP, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon PWG. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis 2008;47:e36-8.
16. John J, Amley X, Bambino G, et al. Torsade de pointes due to methadone use in a patient with HIV and hepatitis C coinfection. Cardiol Res Pract 2010;524764.
17. Dabiesingh DS, Psevdos G, Sharp VL. Atazanavir-associated QT interval prolongation and torsades de points in a patient with liver cirrhosis. Infect Dis Clin Pract 2011;19:226-8.
18. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-95.
19. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYPA inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008;83:153-9.
20. Damle B, Fosser C, Ito K, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol 2009;49:291-300.
21. Vangeneugden T, Sekar VJ, De Paepe E, et al. QTc study of darunavir coadministered with low-dose ritonavir in healthy HIV-negative volunteers. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia, July 22-25, 2007.
22. Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavirboosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. Epub 10 May 2011.
23. Package insert. Invirase (saquinavir). Mississauga, ON: Hofmann-La Roche Limited, November 2010.
24. Busti AJ, Tskikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Medicine 2006;7:317-22.
25. Gianotti N, Guffanti, Galli L, et al. Electrocardiographic changes in HIVinfected, drug-experienced patients being treated with atazanavir. AIDS 2007;21:1648-53.
26. Cotter AG, Satchell CS, Halloran JO, et al. The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 infected patients. 12th International Workshop on Adverse Drug Reactions & Comorbidities in HIV (abstract O10). Antivir Ther 2010;15(suppl 4):A9.
27. Chinello P, Lisena F, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect 2007;54:597-602.
28. Charbit B, Rosier A, Bollens D, et al. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross sectional study. Br J Clin Pharmacol 2009;67:76-82.
29. Drew BM, Ackerman MJ, Funk M, et al. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-60.
30. Reinsch N, Buhr C, Krings P, et al. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials 2009;10:261-8.
31. Soliman EA, Lundgre JD, Roediger MP. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011;25:367-77.
32. Package insert. Reyataz (atazanavir). Montreal, Quebec: Bristol-Myers Squibb Canada, November, 2009.
33. Package insert. Kaletra (lopinavir/ritonavir) St. Laurent, Quebec: Abbott Laboratories, Limited, August, 2009.
34. Package insert. Viracept (nelfinavir). Kirkland, Quebec: Pfizer Canada Inc., May, 2008.
35. Package insert. Prezista (darunavir). Toronto, Ontario: Janssen Inc., June, 2011.